A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies

Trial Profile

A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Cytarabine/daunorubicin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 07 Jun 2016 Results of dose exploration phase of the study (n=9) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top